Molecular insights from dysregulation of the thiazide-sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and thiazide-induced hyponatraemia

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 12, 2013, Pages 876-884

  Glover, Mark ^a   O'Shaughnessy, Kevin M ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Diuretic; Famelial hyperkalaemic hypertension; Gordon syndrome; Hyperkalaemia; Hypertension; Hyponatra emia; Thiazide

Indexed keywords

AMILORIDE; AQUAPORIN 2; BUMETANIDE; CLAVULANIC ACID; CULLIN; CULLIN 3; EPITHELIAL SODIUM CHANNEL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; PHOSPHOTRANSFERASE; POTASSIUM; PROTEIN KINASE WNK1; PROTEIN KINASE WNK4; PROTEIN SERINE THREONINE KINASE; SODIUM CHLORIDE COTRANSPORTER; SPORULATION SPECIFIC PROTEIN 1 RELATED PROLINE ALANINE RICH KINASE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BARTTER SYNDROME; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; ESSENTIAL HYPERTENSION; FLUID INTAKE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GITELMAN SYNDROME; GORDON SYNDROME; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOCALCIURIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY PROXIMAL TUBULE; LIDDLE SYNDROME; LIVER TOXICITY; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; NEPHRON; PHOSPHATE EXCRETION; POTASSIUM URINE LEVEL; SALT INTAKE; SALT WASTING; SALURESIS; SODIUM ABSORPTION; SODIUM BLOOD LEVEL; SODIUM INTAKE; SODIUM URINE LEVEL; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION;

DIURETIC; FAMELIAL HYPERKALAEMIC HYPERTENSION; GORDON SYNDROME; HYPERKALAEMIA; HYPERTENSION; HYPONATRA-EMIA; THIAZIDE;

ANIMALS; DIURETICS; GENETIC PREDISPOSITION TO DISEASE; GITELMAN SYNDROME; HUMANS; HYPONATREMIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MICE; PROTEIN-SERINE-THREONINE KINASES; PSEUDOHYPOALDOSTERONISM; RECEPTORS, DRUG; SODIUM; SODIUM CHLORIDE SYMPORTERS; THIAZIDES;

EID: 84888029094     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12115     Document Type: Article

References (63)

1. National Institute for Health and Care Excellence (NICE). Hypertension: clinical management of primary hypertension in adults. Clinical Guideline CG127. Available from: http://www.nice.org.uk/guidance/CG127 (accessed 10 January 2013).
2. World Health Organization. Global strategy on diet, physical activity and health. 2009. Available from: http://www.who.int/dietphysicalactivity/publications/facts/cvd/en/ (accessed 10 January 2013).
3. The World Health Report. Reducing Risks, Promoting Healthy Life. World Health Organization, Geneva. 2002.
4. Alwan A. Global Status Report on Noncommunicable Diseases 2010. World Health Organization, Geneva, 2011.
5. Joint Health Surveys Unit. Health Survey for England 2006 Latest Trends. Health and Social Information Centre, London. 2008.
6. National Institute of Clinical Excellence (NICE). CG34 Hypertension: full guideline (New recommendations and the evidence they are based on). 2006. Available from: http://www.nice.org.uk/CG034 (accessed 10th January 2013).
7. Dahl LK. Possible role of salt intake in the development of essential hypertension. Int. J. Epidemiol. 2005; 34: 967-72.
8. He FJ, Macgregor GA. Effect of modest salt reduction on blood pressure: A meta-analysis of randomized trials. Implications for public health. J. Hum. Hypertens. 2002; 16: 761-70.
9. Glover M, Mercier Zuber A, O'Shaughnessy KM. Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. Cardiovasc. Ther. 2011; 29: 68-76.
10. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004-BHS IV. J. Hum. Hypertens. 2004; 18: 139-85.
11. Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas. Ann. Med. 1970; 19: 287-94.
12. Gordon RD. The syndrome of hypertension and hyperkalemia with normal glomerular filtration rate: Gordon's syndrome. Aust. N. Z. J. Med. 1986; 16: 183-4.
13. Glover M, Clayton J. Thiazide-induced hyponatraemia: Epidemiology and clues to pathogenesis. Cardiovasc. Ther. 2012; 30: e219-26.
14. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-56.
15. Bobulescu IA, Moe OW. Luminal Na(+)/H(+) exchange in the proximal tubule. Pflugers Arch. 2009; 458: 5-21.
16. Bachmann S, Bostanjoglo M, Schmitt R, Ellison DH. Sodium transport-related proteins in the mammalian distal nephron: Distribution, ontogeny and functional aspects. Anat. Embryol. 1999; 200: 447-68.
17. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat. Genet. 1996; 13: 183-8.
18. + channel, ROMK. Nat. Genet. 1996; 14: 152-6.
19. Simon DB, Bindra RS, Mansfield TA et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat. Genet. 1997; 17: 171-8.
20. Vargas-Poussou R, Huang C, Hulin P et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J. Am. Soc. Nephrol. 2002; 13: 2259-66.
21. Bircan Z, Harputluoglu F, Jeck N. Deletion of exons 2-4 in the BSND gene causes severe antenatal Bartter syndrome. Pediatr. Nephrol. 2009; 24: 841-4.
22. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans. Assoc. Am. Physicians 1966; 79: 221-35.
23. Louis-Dit-Picard H, Barc J, Trujillano D et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat. Genet. 2012; 44: 456-60.
24. Boyden LM, Choi M, Choate KA et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012; 482: 98-102.
25. Canessa CM, Horisberger JD, Rossier BC. Epithelial sodium channel related to proteins involved in neurodegeneration. Nature 1993; 361: 467-70.
26. + channel is made of three homologous subunits. Nature 1994; 367: 463-7.
27. Liddle GW, Bledsoe T, Coppage WS Jr. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans. Assoc. Am. Physicians 1963; 76: 199-213.
28. Cheek DB, Perry JW. A salt wasting syndrome in infancy. Arch. Dis. Child. 1958; 33: 252-6.
29. Chang SS, Grunder S, Hanukoglu A et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat. Genet. 1996; 12: 248-53.
30. Sartorato P, Khaldi Y, Lapeyraque AL et al. Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism. Mol. Cell. Endocrinol. 2004; 217: 119-25.
31. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.
32. Riveira-Munoz E, Chang Q, Bindels RJ, Devuyst O. Gitelman's syndrome: Towards genotype-phenotype correlations? Pediatr. Nephrol. 2007; 22: 326-32.
33. Riveira-Munoz E, Chang Q, Godefroid N et al. Transcriptional and functional analyses of SLC12A3 mutations: New clues for the pathogenesis of Gitelman syndrome. J. Am. Soc. Nephrol. 2007; 18: 1271-83.
34. Glover M, O'Shaughnessy KM. STK39 and WNK kinases: A new target for blood pressure treatment? Curr. Opin. Nephrol. Hypertens. 2011; 20: 16-22.
35. Subramanya AR, Liu J, Ellison DH, Wade JB, Welling PA. WNK4 diverts the thiazide-sensitive NaCl cotransporter to the lysosome and stimulates AP-3 interaction. J. Biol. Chem. 2009; 287: 18471-80.
36. Richardson C, Rafiqi FH, Karlsson HK et al. Activation of the thaizide-sensitive Na-Cl cotransporter by the WNK-regulated kinases SPAK and OSR1. J. Cell Sci. 2008; 121: 675-84.
37. Glover M, Mercier Zuber A, O'Shaughnessy KM. Renal and brain isoforms of WNK3 have opposite effects on NCCT. J. Am. Soc. Nephrol. 2009; 20: 1314-22.
38. Lin S-H, Shiang J-C, Huang C-C, Yang S-S, Hsu Y-J, Cheng C-J. Phenotype and genotype analysis in Chinese patients with Gitelman's syndrome. J. Clin. Endocrinol. Metab. 2005; 90: 2500-7.
39. Rafiqi FH, Glover M, Mercier Zuber A et al. Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol. Med. 2010; 2: 63-75.
40. Wang Y, O'Connell JR, McArdle PF et al. Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc. Natl Acad. Sci. USA 2009; 106: 226-31.
41. Vitari AC, Thastrup J, Rafiqi FH et al. Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1. Biochem. J. 2006; 397: 223-31.
42. Glover M, O'Shaughnessy KM. SPAK kinase-dead knock-in mice are thiazide resistant. J. Hypertens. 2012; 30: 7.
43. Clayton JA, Rodgers S, Blackey J, Avery A, Hall IP. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br. J. Clin. Pharmacol. 2005; 61: 87-95.
44. Roe PF. Hyponatraemia and diuretics. Lancet 1975; 1: 1146-7.
45. Byatt CM, Millard PH, Levin GE. Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions. J. R. Soc. Med. 1990; 83: 704-8.
46. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: Aetiology, assessment and outcome. QJM 2006; 99: 505-11.
47. Arieff Al, Lach F, Massry SG. Neurological manifestations and morbidity of hyponatraemia: Correlation with brain water and electrolytes. Medicine 1976; 55: 121-9.
48. Friedman E, Shadel M, Halkin H, Farfel Z. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann. Intern. Med. 1989; 110: 24-30.
49. Magaldi AJ. New insights into the paradoxical effect of thiazides in diabetes insipidus therapy. Nephrol. Dial. Transplant. 2000; 15: 1903-5.
50. Cesar KR, Magaldi AJ. Thiazide induces water absorption in the inner medullary collecting duct of normal and Brattleboro rats. Am. J. Physiol. 1999; 277: F756-60.
51. Clark BA, Shannon RP, Rosa RM, Epstein FH. Increased susceptibility to thiazide-induced hyponatraemia in the elderly. J. Am. Soc. Nephrol. 1994; 5: 1106-11.
52. Simon DB, Nelson-Williams C, Bia MJ et al. Gitelman's varient of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl transporter. Nat. Genet. 1996; 12: 24-30.
53. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced-myopathy: A genome wide study. N. Engl. J. Med. 2008; 359: 789-99.
54. Formea CM, Myers-Huentelman H, Wu R et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am. J. Transplant. 2004; 4: 1810-17.
55. Biss TT, Avery PJ, Williams MD, Brandao LR, Grainger JD, Kamali F. VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children. J. Thromb. Haemost. 2013; 11: 373-5.
56. Singer JB, Lewitzky S, Leroy EL et al. A genome-wide study identifies HLA alleles associated with lumaricoxib-related liver injury. Nat. Genet. 2010; 42: 711-16.
57. Kindmark A, Jawaid A, Harbron CG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics 2010; 8: 186-95.
58. Hautekeete ML, Horseman Y, Van Waeyenberge C et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroen-terology 1999; 117: 1186-7.
59. O'Donohue J, Oien KA, Donaldson P et al. Co-amoxiclav jaundice: Clinical and histological features and HLA Class II association. Gut 2000; 47: 717-20.
60. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
61. Chung W-H, Hung S-L, Hong H-S et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
62. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat. Biotechnol. 2012; 30: 1117-24.
63. Friedman E, Shadel M, Halkin H, Farfel Z. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann. Intern. Med. 1989; 110: 24-30.